Skip to main navigation Skip to search Skip to main content

MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

  • Irene M. Ghobrial
  • , David Siegel
  • , Ravi Vij
  • , Jeffrey L Wolf
  • , Jesus G. Berdeja
  • , Jeffrey V. Matous
  • , Peter Lipman
  • , Chirag Patel
  • , Trinh Le
  • , Christian Rommel
  • , Gregory Berk
  • Harvard University
  • Hackensack University Medical Center
  • Washington University in St. Louis
  • University of California, San Francisco
  • Sarah Cannon Research Institute
  • Colorado Blood Cancer Institute, Denver, CO, USA,
  • Millennium Pharmaceuticals
  • Former employee of Intellikine, LLC., La Jolla, CA, USA,
  • Intellikine, LLC., La Jolla, CA, USA

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume120
Issue number21
DOIs
StatePublished - Nov 16 2012
Externally publishedYes

Disciplines

  • Medicine and Health Sciences
  • Oncology
  • Internal Medicine

Cite this